Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence
Version of Record online: 27 FEB 2006
Alimentary Pharmacology & Therapeutics
Volume 23, Issue 6, pages 727–733, March 2006
How to Cite
COOPER, B. T., CHAPMAN, W., NEUMANN, C. S. and GEARTY, J. C. (2006), Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Alimentary Pharmacology & Therapeutics, 23: 727–733. doi: 10.1111/j.1365-2036.2006.02825.x
- Issue online: 27 FEB 2006
- Version of Record online: 27 FEB 2006
- Publication data Submitted 19 December 2005 First decision 24 December 2005 Resubmitted 30 December 2005 Accepted 30 December 2005
There is little evidence that treatment of patients with Barrett's oesophagus with proton pump inhibitors over periods up to 6 years results in major regression of Barrett's oesophagus.
To determine if longer periods of treatment with proton pump inhibitors lead to significant regression of Barrett's oesophagus, and to determine the incidence of oesophageal adenocarcinoma in the proton pump inhibitor-treated patients.
We analysed prospectively-collected data on Barrett's oesophagus patients treated with proton pump inhibitors for 1–13 years.
188 patients with Barrett's oesophagus and intestinal metaplasia, were treated for 1–13 years with a proton pump inhibitor (966 years of treatment; mean 5.1 years). No change in length was seen during treatment but 48% of patients developed squamous islands (25% after 1–3 years; 100% at 12–13 years). Squamous islands correlated with treatment duration and male sex but not with proton pump inhibitor dose or patient age. Six patients developed dysplasia and three males developed adenocarcinoma during treatment (cancer incidence 0.31%).
Proton-pump inhibitor treatment over 1–13 years does not shorten the Barrett's oesophagus segment but squamous islands appear in many patients. The incidence of oesophageal adenocarcinoma was low in these proton pump inhibitor-treated patients compared with published series.